Unusual Presentation of Metastatic Hepatocellular Carcinoma in an HIV/HCV Coinfected Patient: Case Report and Review of the Literature

Berretta, Massimiliano; Zanet, Ernesto; Benedetto, Fabrizio Di; Simonelli, Cecilia; Bearz, Alessandra; Morra, Aldo; Bonanno, Santo; Berretta, Salvatore; Tirelli, Umberto

doi:10.1177/030089160809400424

Cited by 8 publications

(4 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To the best of our knowledge, there is only one similar case reported in the literature referred to a HIV/HCV coinfected patient [8].…”

Section: Discussionmentioning

confidence: 98%

And the Hepatocellular Carcinoma Goes to… Masseter!

Silva¹

2016

CSMC

View full text Add to dashboard Cite

A 71-year-old male affected by chronic alcoholism presented with malaise and abdominal pain at the urgency hospital with an HCC suspected on Computed Tomography (CT) scan. A liver biopsy was performed and confirmed the HCC diagnosis. At that time the patient also presented a small mass in the left parotid region. The ultrasonographic evaluation showed a solid heterogeneous nodular lesion with 30x17x25mm embedded in the left masseter muscle, posteriorly to the parotid gland. There was

show abstract

“…To the best of our knowledge, there is only one similar case reported in the literature referred to a HIV/HCV coinfected patient [8].…”

Section: Discussionmentioning

confidence: 98%

And the Hepatocellular Carcinoma Goes to… Masseter!

Silva¹

2016

CSMC

View full text Add to dashboard Cite

show abstract

“…Unfortunately, the outcome for patients with HCC and HIV infection is poor compared with HCC patients who do not have any infection. In these patients, a multidisciplinary approach to therapy will likely represent the key to obtaining efficacy and safety outcomes similar to those in the general population [31][32][33][34][35][36].…”

Section: Discussionmentioning

confidence: 99%

Sorafenib for the treatment of unresectable hepatocellular carcinoma in HIV-positive patients

Berretta¹,

Benedetto²,

Maso³

et al. 2013

Anti-Cancer Drugs

Self Cite

View full text Add to dashboard Cite

Few data are available on the safety and efficacy of sorafenib in HIV-infected patients with unresectable hepatocellular carcinoma (HIV-u-HCC) and concomitant highly active antiretroviral therapy (HAART). Between July 2007 and October 2010, 27 consecutive HIV-u-HCC patients were treated with sorafenib and concomitant HAART within the Gruppo Italiano Cooperativo AIDS e Tumori (GICAT). Three patients achieved a partial response, 12 achieved a stable disease, and 12 showed progression. The median time to progression and overall survival was 5.1 (range 0.5-13.3) and 12.8 (range 1.1-23.5) months, respectively. Grades 3-4 toxicities included diarrhea (four patients, 14.8%), hypertension (three patients, 11%), and hand-and-foot skin reaction (four patients, 14.9%). Most drug-related side effects were low grade and manageable. This retrospective study shows favorable survival data among HIV-u-HCC patients treated with sorafenib together with a reasonable safety profile.

show abstract

“…The proportion of patients coinfected with HCV and HIV-1 who showed detectable antibody responses to ARFP was not significantly different from that of those infected with HCV alone [33,38]. However, further studies testing the anti-F antibody titer in chronic HCV-infected individuals coinfected with other viruses, such as hepatitis B virus (HBV), should be carried out.…”

Section: Hcv-infected Individualsmentioning

confidence: 98%

Positive ratio of specific antibodies to F protein in serum samples from chronic HCV-infected patients using an enzyme-linked immunosorbent assay

Liu¹,

Yu²,

Liu³

2013

European Journal of Gastroenterology & Hepatology

View full text Add to dashboard Cite

We concluded that F protein elicits specific antibodies in most chronic HCV-infected individuals. Further, we confirmed the results of previous reports. The relationship between anti-F protein antibody and HCV coinfection still needs to be confirmed with further studies. Considering the high polymorphism rate of HCV, further studies are still needed for the selection of synthetic peptides from F protein that can coat the wells on microplates and serve as a commercial reagent.

show abstract

Unusual Presentation of Metastatic Hepatocellular Carcinoma in an HIV/HCV Coinfected Patient: Case Report and Review of the Literature

Cited by 8 publications

References 11 publications

And the Hepatocellular Carcinoma Goes to… Masseter!

And the Hepatocellular Carcinoma Goes to… Masseter!

Sorafenib for the treatment of unresectable hepatocellular carcinoma in HIV-positive patients

Positive ratio of specific antibodies to F protein in serum samples from chronic HCV-infected patients using an enzyme-linked immunosorbent assay

Contact Info

Product

Resources

About